Nektar Therapeutics (NKTR) Tops Q4 EPS by 19c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.84 --0%
EPS Growth %: -215.1%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -215.1%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of $0.03, $0.19 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $29.2 million versus the consensus estimate of $29.81 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
- Gogo and Insitu complete satellite connectivity integration for Group 3 UAS
- ProPetro's PROPWR unit signs 230 MW power deal with Targa Resources
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
